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Abstract Texas red-labeled hyaluronan (TR-HA) is rapidly
taken up in a CD44 independent manner into ras-transformed
10T1/2 fibroblasts, where it accumulates in both cell ruffles/
lamellae, the perinuclear area, and the nucleus. HA does not
accumulate in the cell ruffles/lamellae of parental 10T1/2 cells.
Addition of HA to ras-transformed cells promotes their random
motility but has no effect on 10T1/2 cell motility. 10T1/2 cells
can be modified to take up HA into cell ruffles by exposure to
phorbol ester or direct microinjection of HA into cells. Both
treatments significantly stimulate 10T1/2 cell motility.
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1. Introduction
RHAMM is an hyaladherin that occurs at several subcel-
lular loci including the cell surface, cytoplasm and nucleus [1^
3]. An intracellular as well as surface form of RHAMM reg-
ulates cell motility and controls the cell cycle [4,5]. Intracel-
lular RHAMM forms appear to do so at least in part by co-
associating with erk kinase [3] and controlling signaling
through the ras-erk kinase cascade [3,6]. Interestingly, the hy-
aluronan (HA) binding domains of intracellular forms of
RHAMM are required for activation of erk kinase by mutant
active ras and by growth factors that activate ras, such as
PDGF [3]. Several other hyaladherins that are located both
at the cell surface and in the cytoplasm have also been de-
scribed [7^10]. One of these, cdc37 or hsp50, like RHAMM,
regulates cell cycle and motility and in its intracellular form
binds to signaling proteins, such as CDK4 [7,11^13], raf and
src [13^15]. Both the presence of these hyaladherins inside the
cell and their requirement for HA binding domains in activa-
tion of signaling cascades [3] is puzzling since HA has tradi-
tionally been considered to regulate cell behavior by interact-
ing with cell surface receptors [16^18] or by modifying the
extracellular matrix [4,5].
HA is internalized for degradation by an endocytic pathway
that requires CD44 function [19^21]. It is questionable, how-
ever, whether this pathway would allow any association of
HA with the signaling modifying function of intracellular
HA binding proteins. It is therefore intriguing that HA and
other glycosaminoglycans/proteoglycans have previously been
reported to occur intracellularly within cell structures that are
not traditionally associated with the endocytic pathway. For
instance, electron microscopic analysis using gold-labeled ag-
grecan to detect HA indicates the presence of this polysac-
charide within caveoli and the nucleus [22,23], con¢rming ear-
lier subcellular fractionation studies [24,25]. Careful confocal
and functional analyses show the presence of related mole-
cules, such as heparan sulfate and chondroitin sulfate proteo-
glycans, within the nucleus [26^28]. Neither the mechanisms
by which glycosaminoglycans might reach these sites nor their
function at these sites are currently understood or, indeed,
generally focused upon. However, HA has been reported to
bind to chromatin [24,25] and we previously proposed that
intracellular HA may function to regulate key signaling path-
ways that impact on cell cycle and cell motility [1]. Others
have shown that a highly sulfated glycosaminoglycan,
intracellular heparin, regulates transcriptional activation [29^
31].
In an ongoing attempt to assess the mechanisms by which
the HA binding domains of RHAMM regulate ras signaling,
we have assessed whether Texas red-labeled HA (TR-HA) can
be taken up by the cell and accumulate within subcellular
compartments, such as cell processes and the nucleus, sites
that are relevant for MAP kinase signaling cascades [32].
We show here that TR-HA is taken up within minutes of
its addition to ras-transformed cells rapidly accumulating
both around and within the nucleus and cell lamellae by
mechanisms that appear, at least in ras-transformed cells, to
be independent of CD44-mediated uptake [19^21]. Addition
of HA elicits an increase in random cell motility [33]. In con-
trast, the parent 10T1/2 cells do not show a rapid accumula-
tion of HA into lamellae or the perinuclear area and, interest-
ingly, do not respond to HA by increasing their rate of cell
motility. However, treatment of 10T1/2 cells with phorbol
ester, which facilitates HA uptake into these subcellular loca-
tions, or direct microinjection of HA into the cell cytoplasm
signi¢cantly and speci¢cally promotes their random motility.
These results suggest that uptake mechanisms that allow in-
tracellular accumulation of HA in multiple subcellular com-
partments exist and that HA may act here in diverse roles to
control cell behavior.
2. Materials and methods
2.1. Cell culture
Murine 10T1/2 ras-transformed (C3) [34] or RHAMMv4-trans-
fected cells [6] were maintained at 37‡C in 5% CO2 on 100 mm plastic
tissue culture dishes (Nunclon) in DMEM (Gibco BRL) supplemented
with 10% fetal calf serum (FCS) (Intergen) and 10 mM HEPES (Sig-
ma), pH 7.3. Cells were routinely subcultured using 0.25% trypsin
(Sigma) from 80% con£uent cultures and passaged at a 1:10 dilution.
In experiments which required a speci¢c number of cells, a viable cell
count was determined using trypan blue exclusion (0.4% in PBS) and
a hemacytometer.
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2.2. Conjugation of HA with Texas red
700 kDa HA (Hyal Pharmaceutical Corp., Mississauga, Ont.) sus-
pended in 20 mM MES (Sigma), pH 4.5, with 30% ethanol, was mixed
with three-fold excess EDCI (Aldrich) as per the number of HA di-
saccharides. Texas red hydrazide (Molecular Probes) dissolved in
DMF (Aldrich) at a molar ratio of probe to disaccharide of 1:10
was added and the mixture was shaken overnight at room temper-
ature. Unconjugated material was then removed with dialysis in
10 000 molecular weight cut-o¡ membranes (Pierce) against 75 mM
NaCl and 40% ethanol for 4 days in the dark. The product was
lyophilized for storage. Analysis of success of conjugation was con-
ducted with gel permeation chromatography using refractive index
and UV absorption to determine purity and molecular size range of
the bioconjugate.
2.3. Immuno£uorescence
Cells were seeded in DMEM (Gibco BRL) supplemented with 10%
FCS (Intergen) at 60% con£uence on sterile glass coverslips (VWR) in
35 mm tissue culture plates (Costar Corp.). After 8 h, the culture
medium was aspirated, cells were rinsed and medium was replaced
with serum-free DMEM containing 4 mg/ml transferrin (Gibco
BRL) and 4 mg/ml insulin (Sigma) (de¢ned medium) for 12 h. The
cells were then exposed to 150 Wg TR-HA conjugate in 1 ml of de¢ned
medium for varying durations (2 min to 12 h), rinsed twice in cold
5UPBS, and ¢xed in a solution of 2% paraformaldehyde and 1%
cetylpyridinium chloride (CPC) in a 0.1 M Na-phosphate bu¡er pH
7.4 for 10 min at room temperature. Coverslips were then washed
three times for 5 min each in 1UPBS, mounted with elvanol (PVA
15%, glycerin 30%), and viewed on a Zeiss Axiophot 100 confocal
microscope. To ensure that confocal images represented internalized
TR-HA, some cultures were exposed to TR-HA for 10 min, washed,
then digested with Streptomyces hyaluronidase (1 IU/ml at 37‡C for
1 h to remove TR-HA remaining on the cell surface that might inter-
fere with confocal images), ¢xed and examined with a confocal
microscope.
2.4. Digestion of TR-HA with hyaluronidase and competition with
unlabeled HA
Digestion of 150 Wg of TR-labeled HA prior to addition to cells was
carried out in acetate bu¡er pH 5.0, using 15 TRU of Streptomyces
hyaluronidase (Sigma) for 24 h at 37‡C in a proteinase inhibitor bu¡er
(25 mg/ml ovomucoid; 1.0 mg/ml pepstatin A; 18.6 mg/ml iodoacetic
acid; 37 mg/ml EDTA; 17.4 mg/ml PMSF). The mixture was heat-
inactivated at 56‡C for 30 min to destroy enzyme activity. Control
incubations (minus the hyaluronidase) were carried out under the
same conditions. To assess speci¢city of uptake, cultures were also
exposed to TR-labeled HA combined with excess (4 mg/ml) unlabeled
HA.
2.5. Incubation of cells with peptides
150 Wg TR-labeled HA was preincubated with 1 mg/ml of a peptide
that mimics the HA binding domain I, RHAMM (peptideaa423ÿ432
[35]) or 1 mg/ml of a scrambled peptide of domain I which has
been shown not to bind to HA [35], for 2 h at 37‡C prior to cell
treatment as above.
2.6. Anti-CD44 antibody blocking
Ras-transformed cells were preincubated for 30 min at 37‡C with
10^50 Wg/ml of KM201 (RpD Systems) monoclonal anti-CD44 Ab or
KM114 (Pharmingen) monoclonal antibody diluted in 1 ml DMEM
prior to addition of TR-labeled HA.
2.7. Microinjection analysis
10T1/2 ¢broblasts were microinjected with 0.1 or 1.0 ng/ml HA
(MW distribution 60 000^600 000 medical grade, Hyal Pharma, Mis-
sissauga, Ont., Canada) in PBS, together with luciferase yellow to
detect microinjected cells. Control cells were microinjected with PBS
alone or with either 1.0 ng/ml heparin (Sigma Chem. Co.) or 1.0 ng/
ml chondroitin sulfate A and B (Sigma Chem. Co.). Cells were al-
lowed to recover from microinjection for 2 h, then ¢lmed on a heated
stage for 1 h using Empix Northern Exposure image analysis pro-
gram (Empix, Mississauga, Ont.) to quantify random motility. Mi-
croinjection was accomplished using an Eppendorf microinjection
system.
2.8. Exposure of 10T1/2 ¢broblasts to phorbol ester
Phorbol 12-myristate 13-acetate (PMA) was added at 100 nM in
de¢ned media to 10T1/2 cells for up to 4 h in the presence or absence
of 50 Wg/ml cycloheximide, added at the same time. Treated cells were
exposed to unlabeled HA as above and analyzed for motility or to
TR-HA and analyzed for uptake with confocal analysis.
2.9. Cell motility
Ras-transformed and parental 10T1/2 cells were plated at 40% con-
£uence for 24 h and then serum starved for 24^48 h. HA (1 ng to
1 Wg/ml) was added to cells and random locomotion of the cells was
determined by image analysis 1 h later (Northern Exposure, Empix).
Approximately 100 cells were analyzed per experiment.
3. Results
3.1. TR-labeled HA is rapidly taken up and targeted to the
perinuclear area, cell processes and the nucleus of
ras-transformed cells
TR-HA is internalized within subcon£uent monolayers of
ras-transformed cells minutes after its addition, a¡ecting ap-
proximately 90% of cells and rapidly accumulating within
their lamellae and nuclei (Fig. 1). Some general cytoplasmic
and striking perinuclear accumulation is also observed. Opti-
cal sectioning of cells, from which cell surface-bound TR-HA
had been removed with hyaluronidase, suggests an intracellu-
lar location of the TR-HA (Fig. 1). Interestingly, the acute
appearance of TR-HA in ras-transformed cells appears punc-
tate (Fig. 1). Nuclear localization is transient, and by 2 h after
addition nuclear TR-HA is not detected (data not shown).
Streptomyces hyaluronidase-digested TR-HA (Fig. 2a) or
TR-HA mixed with excess unlabeled HA (Fig. 2b) do not
show uptake of the TR label by cells, indicating that unla-
beled HA competes e¡ectively for the uptake of TR-HA and
that the uptake of TR-HA requires larger than tetra- or hexa-
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Fig. 1. Confocal analysis of ras-transformed 10T1/2 cells exposed to
TR-labeled HA. Consecutive optical sections, beginning from the
apical surface of the cell, show TR-HA in the cell processes (indi-
cated by arrow), perinuclear area, and nucleus, 10 min after its ad-
dition in the culture medium. Bar = 10 Wm.
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saccharides. 80^90% of 10T1/2 cells also rapidly internalized
TR-HA and like transformed cells accumulate this polysac-
charide in the nucleus and in the cytoplasm (Fig. 3a). How-
ever, the staining pattern in the nucleus and cytoplasm was
more di¡use than in ras-transformed cells, and 10T1/2 cells
did not accumulate TR-HA as punctate accumulations in cell
lamellae or in the perinuclear area (Fig. 3a).
3.2. Anti-CD44 blocking antibodies do not block rapid uptake
of TR-HA in ras-transformed cells, but RHAMM peptides
block localization of TR-HA to the nucleus
Anti-CD44 function blocking antibodies used at concentra-
tions that have previously been shown to block endocytic
uptake of HA [19,21,36] do not a¡ect nuclear or lamellar
localization of HA in ras-transformed cells (Fig. 2c,d). In
contrast, peptides mimicking an HA binding domain of
RHAMM [35] strikingly block accumulation of HA within
the nucleus (Fig. 2e). Nevertheless, in the presence of these
peptides, HA is still taken up into cell processes and in the
perinuclear area in the presence of this peptide (Fig. 2e). A
scrambled peptide control has no detectable e¡ect on HA
uptake (Fig. 2f). These results suggest that HA accumulation
in the nucleus may require interaction with proteins, possibly
hyaladherins that exhibit RHAMM-like HA binding motifs
[7^9]. As well, these results suggest that the mechanisms di-
recting HA to the nucleus and cell processes/cytoplasm are
distinct.
3.3. Intracellular HA promotes cell motility
HA added to cell cultures promotes the locomotion of ras
(P6 0.05, Fig. 3d), but not 10T1/2 cells (Fig. 3d) (used here at
10 ng/ml but a range from 1 ng to 100 Wg was e¡ective, data
not shown). Addition of phorbol ester to 10T1/2 cells does not
signi¢cantly increase cell motility by itself (P = 0.5, SEM) (Fig.
3d), but permits 10T1/2 cells to increase random locomotion
in response to HA added to culture medium (P6 0.001, SEM)
(Fig. 3d). This e¡ect of phorbol ester is abolished by cyclo-
heximide suggesting the process involves de novo protein syn-
thesis. Interestingly, 10T1/2 cells treated acutely with phorbol
ester now exhibit an intracellular accumulation pattern in the
cytoplasm that resembles ras-transformed cells in that the TR-
HA accumulation is enhanced in cell processes and in the
perinuclear area (Fig. 3b). Furthermore, treatment of cells
with PMA for 4 h (the exposure time to PMA when cells
were analyzed for motility) appears to result in a further en-
hancement of TR-HA uptake (Fig. 3c).
Direct assessment of a role for enhanced cytoplasmic HA in
cell motility is provided by microinjection of HA into the
cytoplasm of 10T1/2 cells (Fig. 4a, 1.0 ng/ml). This signi¢-
cantly promotes random motility (P6 0.0001) (Fig. 4a). In
contrast to HA, microinjection of either 1 ng/ml chondroitin
sulfate (Fig. 4b) or 1.0 ng/ml heparin (Fig. 4c) has no signi¢-
cant e¡ect on cell motility.
These results suggest that ras transformation and phorbol
ester treatment both a¡ect the subcellular distribution of TR-
HA and they may also promote HA uptake, although no
attempt was made here to quantify the amount of HA taken
up by cells. This work, however, is ongoing.
4. Discussion
HA is ubiquitous in the extracellular matrix, and although
its production is acutely upregulated following injury of most
tissues, the function of this in the course of repair has re-
mained elusive [37]. HA production and metabolism are often
altered during tumorigenesis [38] and a causal role for this
modi¢cation has recently been established by a study showing
that HA accumulation around and within colorectal tumor
cells is prognostic of poor outcome [39]. Consistent with the
notion that HA directly regulates cell behavior, study of HA
binding proteins termed hyaladherins has indicated that HA
indeed contributes to the control of cell cycle and cell motility
[1,3,4]. In spite of the importance of these observations, the
molecular mechanisms by which HA directs these processes
are not yet clear. HA regulates protein tyrosine phosphoryla-
tion cascades [1], signaling through growth factors [1,3], actin
cytoskeleton assembly [1,33,40] and activity of MAP kinase
cascades [3], all of which impact on cell motility and/or cell
cycle [34,41]. Most of these actions of HA are considered to
be initiated by HA/cell surface receptor interactions and, con-
sistent with this possibility, many of the e¡ects of HA on
signaling cell motility can be blocked using antibodies to
CD44, RHAMM, cdc37 or p68 [1,4,5,42]. Understanding
the mechanisms of HA/cell surface interactions in signaling
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Fig. 2. Speci¢cty of TR-HA uptake into ras-transformed 10T1/2
cells. a: TR-HA was digested with Streptomyces hyaluronidase prior
to its addition to cells. b: TR-HA was mixed with 4 mg/ml unla-
beled HA, prior to addition to cells. Both treatments abolish cellu-
lar uptake of TR-HA. c,d: Cells were preincubated for 30 min with
anti-CD44 antibodies KM201 (c) and KM114 (d). Neither anti-
CD44 antibody appeared to a¡ect accumulation of TR-HA in cell
processes or in the nucleus. e: TR-HA was preincubated for 2 h
with 1 mg/ml of a peptide mimicking an HA binding domain of
RHAMM [35]. The accumulation of HA within the nucleus is
blocked, but HA is still taken up into cell processes and the perinu-
clear area. f : As in e but using a scrambled peptide, which was not
able to bind to HA. This has no e¡ect on the uptake processes.
Bar = 10 Wm. Arrows indicate TR-HA accumulation in cell proc-
esses.
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has been complicated by the clear role of multiple cell surface-
associated HA binding proteins [4], not all of which are trans-
membrane receptors and some of which (e.g. RHAMM) are
only transiently expressed at the cell surface [1]. A further
complication has arisen from the realization that intracellular
HA binding proteins also exist [1]. Thus, the identi¢cation of
intracellular forms of RHAMM [3], the known occurrence of
cdc37 [43] and p68 [44] in the cytoplasm, their collective abil-
ity to bind to signaling molecules that regulate cell cycle and
motility and the presence of additional, yet uncharacterized,
cytoplasmic HA binding proteins have raised the possibility
that intracellular HA may function in regulating aspects of
cell behavior [1]. The ability of mutant forms of intracellular
RHAMM that are impaired in HA binding to block activa-
tion of erk kinases [3,6] provides further, but still indirect,
evidence for this possibility. Data presented here provide pre-
liminary evidence that further supports this possibility by
demonstrating that cells are able to accumulate HA within
cell processes and the nucleus areas rich in intracellular hy-
aladherins. Further, these events correlate with promotion of
cell motility by HA. The ability of HA, microinjected into
cells that do not naturally take up HA into these compart-
ments, to stimulate cell motility provides the ¢rst direct evi-
dence of an e¡ect of intracellular HA on cell behavior. Col-
lectively, our results suggest that both HA/cell surface
receptor and intracellular HA/protein interactions may be in-
volved in regulation of cell motility. Our results further sug-
gest that the uptake and intracellular targeting of HA is con-
trolled by ras and PKC signaling pathways.
A conceptual problem with assessing the potential functions
of intracellular HA is how this high molecular weight poly-
saccharide is delivered to the cytoplasm and to the nucleus.
Recent cloning of HA synthases [45] predicted that these en-
zymes occur at the cell surface, with the UDP-sugar binding
sites present on the synthase cytoplasmic face. Therefore,
mechanisms must exist that allow extrusion of the large HA
polymer to the extracellular milieu. These mechanisms may
also permit, under certain conditions such as ras transforma-
tion or PKC activation, the re-entry of HA into the cell. It
must also be considered that some HA may not be extruded
but retained within the cytoplasm, where it is therefore avail-
able within a non-endosomal compartment to interact with
key HA binding proteins.
We note here that the rapid uptake of £uorochrome-tagged
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Fig. 3. a: Confocal analysis of 10T1/2 ¢broblasts in an optical section midway through the cell. TR-HA is di¡usely present in the the nucleus
and the cytoplasm and is reduced in the perinuclear area. b: 10T1/2 ¢broblasts treated with 100 nM PMA for 45 min prior to TR-HA addition
show TR-HA localized at the edge of cell processes and in the perinuclear area although nuclear staining remains unchanged. Bar = 25 Wm. c:
10T1/2 ¢broblasts treated with 100 nM PMA for 4 h prior to TR-HA addition show enhanced uptake of TR-HA into cell processes. As well,
an altered cytoplasmic TR-HA distribution is observed which is not seen in ras-transformed cells. d: Addition of HA to ras-transformed 10T1/
2 cells signi¢cantly enhances their motility (also previously reported [33], P6 0.05, Student’s t-test). e: Motility of parental 10T1/2 cells is not
signi¢cantly promoted by HA (10 ng/ml) or PMA alone (100 nM). However, phorbol ester combined with the addition of HA now signi¢cantly
enhances motility (P6 0.001, Student’s t-test). These e¡ects of phorbol ester and HA are abolished by cycloheximide. The bars indicate S.E.M.
of 100 cells. The asterisk indicates signi¢cance. Arrows indicate cell processes.
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HA into ras-transformed cells appears to be independent of
the traditional receptor-mediated endocytic pathway since up-
take is acute, does not appear to be blocked by CD44 anti-
bodies (at least in ras-transformed cells), and results in the
accumulation within cell processes, the nucleus and the peri-
nuclear area [19]. The localization of HA in the nucleus re-
quires an interaction with proteins since exposing cells to pep-
tides that mimic HA binding motifs of RHAMM blocks this
targeting and results in accumulation of HA only within cell
processes. HA binding motifs [35] are found in RHAMM,
cdc37 and p68 and these proteins therefore represent potential
candidates involved in the uptake of HA. Our results also
suggest targeting to cell processes involves a mechanism dis-
tinct from nuclear targeting.
The ability of HA to be directed into 10T1/2 cell processes
after acute phorbol ester treatments suggest an involvement of
protein phosphorylation by protein kinase C in this HA up-
date. This protein serine/threonine kinase has previously been
implicated in cell motility [46] and its kinase activity has also
previously been linked to release of HA from the cell [47],
which may involve analogous mechanisms to uptake noted
here.
A multifaceted role of intracellular HA is suggested by its
localization in the nucleus, previous reports of HA binding to
nuclear proteins [24,25], and the demonstration that a hyalu-
ronan binding protein interacts with RNA splicing machinery
[8]. Our results provide the ¢rst preliminary evidence of the
ability of exogenously added HA to accumulate within multi-
ple subcellular compartments, and to directly a¡ect cell mo-
tility. Further analysis is required to determine the precise
role(s) of HA within the cell, to de¢ne the mechanisms in-
volved in this uptake and accumulation process, and to deter-
mine the signaling processes that intracellular HA might reg-
ulate.
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